A U.S. District Court judge in Delaware has denied Norwich Pharmaceuticals’ motion to modify the court’s final judgment, which blocks the FDA from approving their 550 mg rifaximin generic until Oct. 2, 2029. This decision by Judge Richard G. Andrews bolsters his previous ruling that Norwich’s abbreviated new drug application for rifaximin infringed on Bausch Health’s